retatrutide triple agonist phase 2 obesity trial Retatrutide, a (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Triple Agonist Retatrutide Associated with

This triple action potentially offers enhanced effects compared to dual or single-receptor medications

While these effects are beneficial in metabolic regulation, they also underline the most reported adverse effects, namely, nausea, vomiting, and diarrhea, all gastro-intestinal related, particularly during the initiation or rapid dose escalation of therapy

However, deciding whether a new treatment is suitable requires looking beyond early results and considering personal health needs, treatment goals and available evidence

This side effect can show up in the form of brain fog, poor physical performance, irritability, forgetfulness, and more

The study found that proline and glycine play a role in facilitating the correct arrangement of residues for the acyl transfer